Physician profile
Ajaz L Chaudhry
NPI 1356507115
$6,195.28
in general payments reported to CMS, 2019-2025
21 companies · $1,559 in 2025
The $1,559 reported for 2025 was more than what 86% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $962 · 2020: $465 · 2021: $618 · 2022: $813 · 2023: $545 · 2024: $1,234 · 2025: $1,559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,337.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $2,183.46 | 2019-2025 | Xpress Loprofile, Scopis Ent, Hemopore |
| Inspire Medical Systems, INC. | $956.81 | 2019-2025 | Inspire |
| Aerin Medical INC. | $732.71 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $731.67 | 2019-2025 | Dupixent |
| Genzyme Corporation | $374.13 | 2019-2025 | |
| Medtronic, INC. | $287.06 | 2022-2025 | Propel, Sinuva, Pteye Parathyroid Detection System |
| Optinose US, INC. | $227.71 | 2019-2025 | |
| Olympus America INC. | $135.55 | 2021-2023 | Rhino-Laryngo Videoscope, Rhino-Laryngo Fiberscope |
| Intersect Ent, INC. | $111.86 | 2019-2020 | |
| Acclarent, INC | $110.93 | 2020-2022 | |
| Glaxosmithkline, LLC. | $94.70 | 2021-2024 | Nucala |
| Ambu INC. | $68.89 | 2022-2024 | |
| Alk-Abello, INC | $38.98 | 2019-2022 | |
| Organogenesis INC. | $28.35 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $18.19 | 2025 | Tezspire |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $17.40 | 2019 | |
| Amgen INC. | $16.76 | 2025 | |
| Paratek Pharmaceuticals, INC. | $16.02 | 2025 | Xhance |
| Lilly USA, LLC | $15.85 | 2025 | Zepbound |
| Resmed Corp | $14.83 | 2024 | |
| Novo Nordisk INC | $13.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajaz Chaudhry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.